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Abstract 
 
BACKGROUND: Acute encephalitis and encephalopathy (AEE) are life-threatening diseases in 
children. However, no laboratory examinations are performed for their early diagnosis and 
treatment. Alpha 2-macroglobulin (α2M) is a blood glycoprotein that increases at the early 
stages of inflammation. In this study, we investigated whether α2M was associated with AEE. 
METHODS: We analyzed the association between AEE and α2M using cerebrospinal fluid 
(CSF) and serum samples from patients with acute disseminated encephalomyelitis (ADEM), 
infection-related acute encephalopathy (AE), febrile status epilepticus (FSE), and febrile seizure 
(FS). Samples were collected in the pediatric department of hospitals throughout Fukushima 
Prefecture between January 1, 1999, and May 31, 2012. 
RESULTS: α2M levels in the CSF were quantified at 4.7 (3.8–8.4) μg/mL for ADEM, 2.1 (1.1–
2.3) μg/mL for AE, 1.1 (0.9–6.4) μg/mL for FSE, and 1.0 (0.8–1.1) μg/mL for FS. α2M levels in 
patients with ADEM were significantly higher than those in patients with AE and FS (p = 0.019 
and p = 0.002, respectively). The ratio of the α2M level in the CSF to that in the serum in 
patients with ADEM was significantly higher than that in patients with FSE (p = 0.04). In 
patients with ADEM, α2M levels in the CSF decreased with treatment. 
CONCLUSIONS: Our results suggest that the ratio of the α2M level in the CSF to that in the 
serum reflects the neuroinflammatory status of patients with ADEM and indicates the 
expression of early neuroinflammation in ADEM. 
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Introduction 
Acute encephalitis and encephalopathy (AEE) can result in various sequelae, including death; 
hence, early intervention is required. Although AEE occurs with a low frequency, it is common 
in infants in East Asia (1). It results from various causes, including viral infections and 
connective tissue disease; moreover, pathologies related to immune conditions are different and 
have not yet been clarified. Therefore, AEE diagnosis is based on a comprehensive assessment 
of each patient’s clinical course, laboratory examinations, head imaging, and 
electroencephalogram findings. However, in the acute phase, particularly when the patient is in 
a critical condition, diagnosis is often challenging because of the difficulty associated with 
conducting adequate examinations. In other words, these diseases are difficult to distinguish 
based on clinical presentations, despite the difference in pathologies. 
Acute encephalitis is classified into viral and non-viral encephalitis. The most common viral 
encephalitis is herpes encephalitis, whereas the most common non-viral encephalitis types 
include acute disseminated encephalomyelitis (ADEM) and non-herpetic acute limbic 
encephalitis (ALE). In viral encephalitis, viral pathogen isolation or gene detection is directly 
linked to its diagnosis. The herpes simplex virus is the most common cause of encephalitis in 
western countries. Herpes simplex encephalitis occurs at all ages during infancy and childhood, 
with peak incidence during the first year of life (2). For non-viral encephalitis, diseases in which 
autoantibodies are involved in the pathology have recently been clarified, such as the 
anti-N-methyl-D-aspartic acid receptor antibody in non-herpetic ALE. Nevertheless, the 
pathology of ADEM remains unclear. 
Acute encephalopathy (AE) is classified as being either related or unrelated to infectious 
diseases. Infectious disease-related AE is a generic term for a wide range of cerebral 
dysfunctions accompanying infectious diseases, although no finding has suggested pathogen 
invasion in the central nervous system (CNS). On the contrary, encephalopathy unrelated to 
infectious diseases is a brain dysfunction accompanying various non-infectious diseases, such as 
liver failure, renal failure, and hypertension. Febrile seizure (FS) is a generic term for the 
condition in which convulsions appear transiently during a fever. FS is a common disease in 
children and has a good prognosis without clinical sequelae. As the initial clinical symptoms of 
ADEM, AE, and FS are similar, these diseases are difficult to differentiate in the acute phase. 
Many cytokines and biochemical proteins have been studied as biomarkers of AEE. Reportedly, 
levels of inflammatory cytokines in the cerebral spinal fluid (CSF) increase during the acute 
phase, and studies have reported the role of interferon-gamma in acute encephalitis; the role of 
interleukin-6 (IL-6) and IL-8 in bacterial meningitis; and the role of tumor necrosis factor 
(TNF)-alpha, soluble TNF receptor-1, and IL-6 in AE (3, 4). On the contrary, regarding 
biochemical proteins in the CSF, S-100B, glial fibrillary acidic protein (GFAP), and tau protein 
have been reported as brain injury biomarkers of AE (5–8). These biomarkers represent the 
repair process of damaged nerve cells and axons. Therefore, they are not suitable for expressing 
neuroinflammation in the acute phase. 
Alpha 2-macroglobulin (α2M) can be an indicator of acute inflammation, which is a biological 
defense response, unlike the previously reported damaged substances resulting from cytotoxicity, 
such as S-100 B, GFAP, and tau protein. We focused on α2M, whose blood level increased in a 
short time at the onset of inflammation. An increase in α2M levels in the CSF in bacterial 
meningitis has been reported (3, 9, 10). Extensive studies have been conducted on the 
relationship between α2M levels in the CSF and CNS diseases in patients with bacterial 
meningitis, showing that α2M levels in the CSF reflected α2M produced in the serum during 
systemic inflammation due to the damage to the blood–brain barrier (BBB) (3, 10–12). However, 
there have been no reports on α2M levels in patients with ADEM. 
 In this study, we aimed to measure α2M levels in the CSF and serum samples of patients with 
ADEM, AE, febrile status epilepticus (FSE), or FS in the acute phase and to examine the 
association between neuroinflammation and α2M. 
 
Materials and Methods 
Sample collection 
Participants 
We analyzed preserved samples collected from 35 patients with ADEM, AE, FSE, and FS who 
were treated in the pediatric departments of hospitals throughout Fukushima Prefecture between 
January 1, 1999, and May 31, 2012. These samples were stored to assess cytokine levels and 
conduct viral polymerase chain reactions (PCRs). The first diagnosis was provided based on the 
findings on admission, and it was confirmed by the clinical course. A presumable diagnosis of 
ADEM was clinically made based on alterations to or a loss of consciousness lasting > 24 h, 
presenting with acute polysymptomatic neurological signs, and cranial/spinal imaging showing 
one or multiple lesions suggestive of demyelination. A presumable diagnosis of AE was 
clinically established based on the acute onset of impaired consciousness accompanied by brain 
dysfunction, usually preceded by infection (1, 13). The FS group consisted of children who 
presented with fever and seizures; however, they were later found to be free from acute 
neurological damage based on the course of clinical events, laboratory data, and brain imaging, 
where available. FSE was diagnosed in patients with FS who presented with seizures lasting for 
> 30 min. CSF samples from patients with bacterial meningitis were used as positive controls, 
and patients with leukemia in remission with no neurological abnormality confirmed by regular 
examinations were used as negative controls. Patients with viral meningitis, myelitis, or vascular, 
metabolic, endocrine, or toxic disorders were excluded. 
 Preservation of CSF and serum samples 
CSF and serum samples were all collected within 24 h after disease onset. These samples were 
immediately centrifuged after collection and stored at −80°C. Patients who provided samples in 
which macroscopic hemolysis was observed were excluded from the analysis. 
 
Ethics 
Preserved samples were used in this study. This study was conducted with the approval of the 
Ethics Committee of the Fukushima Medical University (approval no. 1684). Information 
related to this research was released on our university website, and patients were included in the 
study using an opt-out methodology. 
 
Immunoblotting 
The protein concentration of clinical samples was quantified using a BCA Protein Assay Kit 
(ThermoFisher Scientific, Waltham, MA, USA). CSF samples were diluted with a sample 
loading buffer and heated at 95°C for 5 min, and then electrophoresed at 200 mV, 20 mA/sheet, 
for 73 min using a 5%–20% gradient polyacrylamide gel (Wako, Osaka, Japan). Clinical 
specimens with a total protein content of 0.4 μg and 2 ng of human plasma α2M (Sigma-Aldrich, 
St. Louis, MO, USA) as a standard were electrophoresed. The gel of <15 kDa was cut out from 
the main gel and subjected to silver staining (Wako) to detect transthyretin as a banding control. 
It was then transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, USA) 
at 300 V, 350 mA, for 45 min by wet western blotting. After blocking for 1 h at room 
temperature under 3% milk phosphate-buffered saline containing Tween-20 (PBST), the 
membranes were reacted with 3 μg/mL of anti-α2M antibody (ICN/Cappel, Aurora, OH, USA) 
and diluted with 3% milk PBST for 2 h. After washing three times with PBST, the membranes 
were reacted with horseradish peroxidase (HRP)-labeled anti-goat IgG antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA), diluted to 0.08 μg/mL with 3% milk 
PBST for 1 h, and then washed in the same way with PBST. Immunoreactive bands were 
detected using a SuperSignal® West Dura Extended Duration Substrate (ThermoFisher). The 
band intensity was calculated using an Image Saver 6 luminescence detector (ATTO, Tokyo, 
Japan). 
 
Enzyme-linked immunosorbent assay (ELISA) 
For ELISA, 100 μL of anti-human α2M antibody (2.0 μg/mL; ICN/Cappel Pharmaceuticals) 
diluted with 0.05 M carbonate–bicarbonate (pH 9.6) was added to each well of a 96-well C8 
MaxiSorp™ immunomodule plate (Nunc, Roskilde, Denmark) and incubated at 4°C overnight. 
After washing once with Tris-buffered saline containing Tween-20 (TBST), 300 μL of 10% 
Block Ace (DS Pharma Biomedical, Osaka, Japan) was added to each well and incubated as a 
blocking step for 1 h. After washing five times with TBST, 0.75 μL of each CSF sample was 
applied to each well and incubated at 37°C for 1 h. After washing again five times with TBST, 
the plate was incubated with 100 μL of HRP-conjugated anti-human α2M antibody (2.0 μg/mL; 
GeneTex, San Antonio, TX, USA) at room temperature for 1 h. After further washing five times 
with TBST, the plate was reacted with 3, 3', 5, 5'-tetramethylbenzidine peroxidase substrates 
(Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA). The reaction was quenched 
using 1 M hydrochloric acid, and the absorbance at 450 nm was measured with a microplate 
reader (Bio-Rad Laboratories). 
 
Immunohistochemistry 
Formalin-fixed paraffin-embedded brain tissue infected with herpes encephalitis was cut into 
5-μm-thick sections using a microtome and mounted on glass slides. Deparaffinized sections 
were incubated with or without anti-human α2M antibody (goat IgG, AF1938, R&D 
SYSTEMS)followed by biotinylated rabbit anti-goat IgG (Nichirei, Tokyo, Japan). The antigens 
were visualized with avidin–biotin peroxidase complex and peroxidase DAB enzyme 
histochemistry. Sections were then counterstained with cresyl violet and cover-slipped. 
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 21 (IBM Japan, Ltd., Tokyo, 
Japan). Continuous variables were expressed as medians (interquartile range). Comparisons 
between groups were made using the Kruskal–Wallis test. Thereafter, comparisons between two 
groups were made using the Mann–Whitney U test. A p-value < 0.05 was considered 
statistically significant. 
 
Results 
Patient characteristics 
Table 1 shows the characteristics of patients according to the diagnosis. In total, 35 patients (17 
boys, 48.6%, and 18 girls, 51.4%) were enrolled. The age at disease onset ranged from infancy 
to school aged. No significant differences were found in their age at diagnosis. 
 
General examination findings 
The number of cells in the CSF and the white blood cell count in blood, as well as the 
C-reactive protein (CRP) levels in the blood samples, are shown in Table 2. The median number 
of cells in the CSF was 41.5 (27.8–49.0)/μL for patients with ADEM, 2.0 (1–2.5)/μL for those 
with AE, 1.5 (1.0–2.8)/μL for those with FSE, and 5.0 (1.0–7.0)/μL for those with FS. The 
number of cells in the CSF samples from patients with ADEM was significantly higher than 
those from patients with AE, FSE, and FS (p = 0.02, 0.01, and 0.04, respectively). On the 
contrary, no significant differences were found in the number of cells in the white blood cell 
count or CRP levels among the blood samples. 
 
Detection of α2M in CSF by western blotting 
A 180-kDa α2M band (Fig. 1) was detected in all CSF samples from patients with AE, ADEM, 
FSE, and FS. Strong bands were detected in two samples (nos. 1 and 2) from patients with 
ADEM. Samples from patients with bacterial meningitis, in whom α2M levels in the CSF were 
reported to increase markedly, were used as positive controls (no. 11). A strong band was also 
detected in the other sample from patients with AE, but most other samples had weak bands. In 
addition, the bands of the control samples were weak (nos. 9 and 10). 
  
Quantification of α2M in CSF and serum by ELISA 
To confirm the results of the western blot analysis, we performed sandwich ELISA for α2M 
using the CSF and serum samples (Table 3). The median α2M level (interquartile range) in the 
CSF was 4.7 (3.8–8.4), 2.1 (1.1–2.3), 1.1 (0.9–6.4), and 1.0 (0.8–1.1) μg/mL in patients with 
ADEM, AE, FSE, and FS, respectively. The α2M level in patients with ADEM was significantly 
higher than those in patients with AE and FS (p = 0.019 and p = 0.002, respectively). For 
reference, the α2M level in the CSF from patients with bacterial meningitis (n = 4) and control 
patients (n = 18) was 24.0 (6.9–25.2) and 1.54 (1.3–2.0) μg/mL, respectively (data are not 
shown). On the contrary, the median α2M level in the serum of patients was 363.9 (352.3–
380.8) mg/dL in ADEM, 353.8 (328.7–429.7) mg/dL in AE, 356.4 (335.1–392.3) mg/dL in FSE, 
and 263.6 (174.7–284.9) mg/dL in FS. No significant differences were observed in α2M levels 
in the serum among the diseases. The ratio of the α2M level in the CSF to that in the serum was 
examined, and the median value of this ratio in patients with ADEM was significantly higher 
than those in patients with AE and FSE (p = 0.016 and p = 0.04, respectively). 
 
Scatter diagram of α2M levels in CSF and serum 
To investigate the correlation between α2M levels in the CSF and serum, we plotted α2M levels 
in 10 paired samples of the CSF and serum from five patients with ADEM and five patients with 
AE (Fig. 2). α2M levels in the CSF differed markedly among patients with ADEM, regardless 
of α2M in their serum. There was almost no correlation between α2M levels in the CSF samples 
and those in the serum samples (R = 0.264, p = 0.668) from patients with ADEM. On the 
contrary, in patients with AE, α2M levels in the CSF were low. 
 Receiver operating characteristics (ROC) curve 
To distinguish ADEM from the other diseases (AE, FSE, and FS) based on the ratio of α2M 
levels in the CSF and in serum, ROC curve analysis was performed (Fig. 3). The α2M cutoff 
level, according to Youden’s index (sensitivity + specificity − 1), was 0.42 μg/mg. The 
sensitivity and specificity were 1.00 and 0.79, respectively. Furthermore, to analyze α2M levels 
in the CSF, the cutoff level was set as 2.5 μg/mL. The sensitivity was 1.00 and specificity was 
0.80, which were almost the same as those for the ratio of the α2M level in the CSF and that in 
the serum. 
 
Changes in α2M band levels in the CSF of patients with ADEM after treatment 
We examined the temporal changes in α2M band levels in the CSF (Fig. 4). Compared with 
CSF samples obtained at disease onset, α2M band levels decreased after steroid pulse therapy 
(no. 1 vs. no. 2 and no. 3 vs. no. 4). On the contrary, in samples obtained from a patient before 
being diagnosed with ADEM who did not receive therapeutic intervention, no significant 
decrease was found in the band levels even 10 days after disease onset (no. 5 vs. no 6). 
 
α2M immunoreactive cells in herpes viral encephalitis 
To examine α2M production in the CNS, the tissue sections of patients with herpes simplex 
encephalitis were subjected to immunohistochemistry. As shown in Fig. 5A, astrocyte-like cells 
(arrow) and microglia-like cells (circle) were immunoreactive against anti-α2M antibodies. 
Vascular endothelial cells were also immunoreactive (asterisk). Many macrophage-like cells 
were also immunoreactive in the perivascular Virchow–Robin spaces of blood vessels (data not 
shown). No immunoreactive signal was observed without the first antibody (Fig. 5B).  
 
Discussion 
α2M is a glycoprotein with a molecular weight of 725.000, making it one of the most polymeric 
substances among the plasma proteins, and it exhibits a mass of approximately 180 kDa by 
electrophoresis (14). α2M is produced in the Kupffer cells of the liver during the early stage of 
inflammation, and it appears in the blood. Regarding its function in the blood in vivo, α2M is 
known to non-specifically capture proteases released from bacteria and act as a protease 
inhibitor, resulting in the inhibition of cellular immunity (15). α2M is characterized by its rapid 
response, which is more rapid than antigen–antibody reactions. After capturing proteases, α2M–
protease complexes are taken up by α2M receptors on the surfaces of hepatocytes, macrophages, 
fibroblasts, and mast cells. Therefore, the complexes disappear from the blood upon the 
resolution of the inflammation (16, 17). 
In this study, α2M levels in the CSF of patients with ADEM were higher than those in patients 
with AE, FSE, and FS (Fig. 1). α2M levels in the CSF and serum from patients with bacterial 
meningitis showed a significantly strong correlation (r = 0.74, p < 0.0001) (3). In other words, it 
appears that α2M in the case of bacterial meningitis is produced by the liver and that α2M levels 
in the CSF increase as a result of the concentration gradient of α2M in the serum. Kanoh et al. 
concluded that α2M levels in the CSF of patients with bacterial meningitis increase as a result of 
the permeation of α2M from the serum to the CSF. α2M has a large molecular weight, so this 
permeation depends on the degree of inflammation-induced BBB damage (10). However, no 
studies on α2M levels in the CSF of patients with ADEM have been reported. A significant 
difference was found in α2M levels in the CSF between patients with ADEM and those with AE, 
whereas no significant differences were observed in serum α2M levels of patients with these 
diseases (Table 3). 
ADEM is defined as the first episode of inflammatory demyelination, with polyfocal 
neurological deficits implicating the involvement of multiple sites of the CNS (18). There have 
been no reports on vascular permeability in patients with ADEM. Furthermore, the mechanism 
relating to the extent of BBB damage and the concentration gradient of serum α2M is yet to be 
elucidated. In patients with ADEM, α2M levels in the CSF are not correlated with those in the 
serum, suggesting that α2M is produced in the CNS (Fig. 2). Serum α2M plays an important 
role as a carrier protein for IL-6 and activates IL-6 produced at local inflammatory sites (19). 
Our present results indicate that astrocyte-like cells may produce α2M in brain tissues (Fig. 5). 
This observation is supported by neuroinflammation relating to a microglia–astrocyte–mast cell 
network (20). In addition to findings from patients with CNS infections, such as herpes simplex 
encephalitis, those from patients with neurodegenerative diseases, such as Alzheimer’s disease, 
multiple sclerosis, and Parkinson’s disease, also demonstrates neuroinflammation induced by 
glial cells of the brain (21). To date, there have been no reports on α2M production in the brain. 
The results of our study suggest that α2M is, at least partly, produced in the CNS under 
inflammatory conditions.  
In ADEM, it is unknown whether the increase in α2M is due to brain production or vascular 
permeability. The mechanism of neuroinflammation is related to microglia and mast cells, 
which act as macrophages in the brain and react with cytokines, chemokines, and 
neurotransmitters. When lesions form in CNS, microglia are activated to produce inflammatory 
cytokines and mediate inflammatory responses to disease or injury. One of these responses may 
be α2M production. 
We investigated whether α2M levels in the CSF could be used clinically. α2M levels in the CSF 
and the ratio of the α2M level in the CSF to that in the serum were significantly elevated in the 
acute phase of ADEM. On the contrary, a comparison of the α2M bands in the CSF samples 
obtained at disease onset and after treatment showed that the bands were weaker after steroid 
pulse treatment. However, in a patient not receiving treatment, the α2M bands remained strong 
over time (Fig. 4). Changes in α2M levels in the CSF may have reflected the effect of 
intervention. These data suggest that the ratio of the α2M level in the CSF to that in the serum 
reflects the neuroinflammatory status of patients with ADEM and indicates the expression of 
early neuroinflammation in ADEM. 
 
Limitations 
In this study, pathogens are not clearly known in any AEE cases. In addition, as our study uses 
only a small number of samples, further accumulation of data is warranted. Finally, the presence 
of α2M in the CSF does not indicate disease specificity; therefore, the results should be 
interpreted quantitatively, considering the clinical course. 
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Figure legends 
Fig. 1: Western blotting of CSF samples 
(A) The same quantity of CSF protein (0.4 µg) was applied to each lane. Western blotting was 
performed using anti-sheep α2M antibody. Nos. 1 and 2 are for patients with ADEM, 3 
and 4 are for patients with AE, 5 and 6 are for patients with FSE, and 7 and 8 for patients 
with FS. Migrating positions of molecular weight markers (150 and 250 kDa) are indicated 
by arrows (far left of the figure). The bands for leukemia in remission (nos. 9 and 10) and 
that for bacterial meningitis (no. 11) are shown on the far right side of the figure. 
(B) Silver staining was performed and a gel < 15 kDa was used as a loading control. 
 α2M, alpha 2-macroglobulin; ADEM, acute disseminated encephalomyelitis; AE, acute 
encephalopathy; CSF, cerebrospinal fluid; FSE, febrile status epilepticus; FS, febrile seizure. 
 
Fig. 2: Scatter diagram of α2M levels in the CSF and serum 
α2M levels in the CSF and serum are plotted along the vertical and horizontal axes, respectively. 
Closed circles represent α2M levels in patients with ADEM and open circles represent those in 
patients with AE. The boxed area in the figure is the reference range of α2M levels in the serum. 
 α2M, alpha 2-macroglobulin; ADEM, acute disseminated encephalomyelitis; AE, acute 
encephalopathy; CSF, cerebrospinal fluid. 
 
Fig. 3: Receiver-operator characteristic curve for the ratio of the α2M level in the CSF to that in 
the serum. At a cutoff level of 0.42 μg/mg, the sensitivity and specificity for ADEM were 1.00 
and 0.79, respectively 
 α2M, alpha 2-macroglobulin; ADEM, acute disseminated encephalomyelitis; CSF, 
cerebrospinal fluid. 
 
Fig. 4: Changes in α2M band levels in the CSF after treatment for ADEM 
Paired samples of the CSF (on disease onset and after treatment) were obtained from patients 
with ADEM. Western blotting was performed in the same manner as in Fig. 1. Nos. 1 and 3 
show α2M bands at onset, and nos. 2 and 4 show their α2M bands after steroid pulse therapy. 
Both α2M levels decreased after treatment. On the contrary, there was no change in α2M bands 
between nos. 5 and 6, obtained at a 10-day interval from a patient before being diagnosed with 
ADEM. 
 α2M, alpha 2-macroglobulin; ADEM, acute disseminated encephalomyelitis; CSF, 
cerebrospinal fluid. 
 
Fig. 5: α2M immunoreactive cells in herpes simplex encephalitis 
On encephalitis tissue, astrocyte-like cells (arrow) and microglia-like cells (circle) were 
immunoreactive against anti-α2M antibodies (A). Vascular endothelial cells were also 
immunoreactive (asterisk). No immunoreactive signal was observed without the first 
antibody and only signals of counter staining with cresyl violet were observed (B). 
Table 1: Patient Characteristics
ADEM AE FSE FS
n 5 7 12 11
Age, y, median
(interquartile range)
4.4
(1.0–11.4)
2.3
(0.7–7.0)
1.1
(0.6–4.4)
2.6
(0.3–7.3)
Sex (B:G) 1:4 4:3 6:6 6:5
ADEM: acute disseminated encephalomyelitis; AE: infection-related acute 
encephalopathy; FSE: febrile status epilepticus; FS: Febrile seizure simplex type
B:boys, G:girls
Table 2: CSF cells,  WBC and CRP levels in serum samples 
ADEM AE FSE FS
CSF cells (/μl) 41.5*
(27.8–49.0)
2.0
(1.0–2.5)
1.5
(1.0–2.8)
5.0
(1.0–7.0)
WBC (/μl) 13000
(10200–15400)
10700
(8750–13750)
10900
(8300–16538)
12900
(-)
CRP (mg/dl) 0.97
(0.53–1.26)
0.16
(0.10–0.67)
0.96
(0.37–1.57)
1.2
(-)
The number of CSF samples : ADEM (n=5), AE (n=7), FSE (n=12), and FS(n=11). 
The number of serum samples : ADEM (n=3), AE (n=7), FSE (n=10), and FS (n=1).  
CSF cells: Cerebral spinal fluid cells; WBC: white blood cell; CRP: c-reactive protein. 
All concentrations are expressed as median level (interquartile range).
*P-values (<0.05) for CSF cells are detected vs AE, FSE, and FS. 
Table 3：α2M levels in CSF, serum, and ratio in CSF to serum
ADEM AE FSE FS
CSF
(μg/ml)
4.7 *
(3.8–8.4)
2.1
(1.1–2.3)
1.1
(0.9–6.4)
1.0
(0.8–1.1)
Serum 
(mg/dl)
363.9
(352.3–380.8)
353.8
(328.7–429.7)
356.4
(335.1–392.3)
263.6
(174.7-284.9)
CSF/Serum
(μg/mg)
1.46 **
(0.75–2.28)
0.28
(0.27–0.34)
0.3
(0.27–0.50)
0.17
(-)
The number of CSF samples : ADEM (n=5), AE (n=7), FSE (n=12), and FS(n=11).                 
The number of serum samples : ADEM (n=8), AE (n=6), FSE (n=13), and FS (n=3).  
The ratio in CSF to serum(CSF/Serum) : ADEM (n=5), AE (n=5), FSE (n=8), and FS (n=1).  
All concentrations and ratio are expressed as median level (interquartile range).
*P-values (<0.05) for CSF cells are detected vs AE and FS. 
**P-values (<0.05) for CSF cells are detected vs AE and FSE. 
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the membranes were reacted with 3 μg/ml of anti-α2M antibody (cappel;ICN, Aurora, OH, USA) 
100 μl of HRP-conjugated anti-human α2M antibody (2.0 μg/ml; GeneTex, San Antonio, TX, USA) 
The specificity of anti-human alpha2M antibodies were 
verified by each producer. To further confirm the 
specificity we performed westernblot analysis. On the 
blot R&D antibody used for immunohistochemistry  reacts 
a single band, which comigrates with purified alpha2M. 
ICN antibody used for westernblot analysis also reacts 
with a band comigrating with purified alpha2M. Faint 
signal around 60 kDa appears to be non-specific binding 
to albumin, which is contained at  1 microgram/mL.
Combination of Cappel capture antibody and Gene Tex
detection antibody were used for ELISA. The ELISA 
revealed that CSF contains 2 ng alpha2M/microliter, which 
is consistent with the signal on the blot, comparing 
purified alpha2M. These results suggest that the 
antibodies used are specific to alpha2M with minimum 
background signal. 
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